IDEAYA Biosciences, Inc.
IDYA

$2.21 B
Marketcap
$25.61
Share price
Country
$0.82
Change (1 day)
$47.74
Year High
$24.48
Year Low
Categories

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

marketcap

IDEAYA Biosciences, Inc. (IDYA) - Company Outlook



Company Outlook

Year Receivables Debt Liabilities Assets Current Assets
2023 18 K -154,146,000 28.23 M 649.32 M 532.63 M
2022 211 K -65,150,000 387.97 M 387.97 M 370.45 M
2021 1.1 M -86,865,000 381.35 M 381.35 M 251 M
2020 1.88 M -65,314,000 298.27 M 298.27 M 288.61 M
2019 -27,295,000 113 M 113 M 100.48 M